Product Introduction
Bioactivity


英文名: Indantadol HCl

描述: Indantadol HCl (CHF-3381) 是一种 NMDA 拮抗剂和非选择性 MAO 抑制剂。

体内活性: In a human heat-capsaicin-induced pain model, Indantadol HCl at a dose of 500 mg effectively reduced the area of secondary hyperalgesia to 67%. Indantadol HCl undergoes extensive liver metabolism, withthe formation of two major metabolites - CHF-3567 and 2-aminoindane. The drug is excreted in urine partially as the parent compound, but mostly as CHF-3567. The tolerability profile of Indantadol HCl at single doses up to 600 mg and twice-daily doses up to 400 mg in clinical trials was significantly more favorable than for other NMDA antagonists. Most side effects have been observed to be mild, and include dizziness and asthenia. Indantadol HCl is currently in phase II clinical trials in patients with diabetic peripheral neuropathic pain.[1]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (220.56 mM)


关键字: CNP3381 | CHF 3381 | GT3381 | CMP3381 | V3381 | CMP 3381 | CNP 3381 | Indantadol HCl | GT 3381 | CHF3381 | V 3381

相关产品: Allylthiourea | Cassiaside B2 | 8alpha-Tigloyloxyhirsutinolide 13-O-acetate | Azure B | hMAO-B-IN-5 | Ladostigil | Safinamide | Hydralazine hydrochloride | Pargyline hydrochloride | CR4056

相关库: Drug Repurposing Compound Library | Anti-Neurodegenerative Disease Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Bioactive Compound Library